ARDX · Insider Trading
Ardelyx, Inc.
Every open-market purchase and sale reported by ARDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Susan Hohenleitner | Chief Financial Officer | Sell | −1,558 | −$6.01K |
| 2026-08-25 | Joseph James Reilly | See Remarks | Sell | −3,982 | −$15.36K |
| 2026-08-25 | James Parker Brady | Chief Human Resources Officer | Sell | −15,136 | −$58.38K |
| 2026-08-25 | John E Bishop | See Remarks | Sell | −19,750 | −$76.17K |
| 2026-08-25 | Mike Kelliher | Chief Business Officer | Sell | −7,758 | −$29.92K |
| 2026-08-25 | Michael Raab | President & CEO | Sell | −58,574 | −$225.91K |
| 2026-08-25 | Laura A Williams | Chief Patient Officer | Sell | −10,739 | −$41.42K |
| 2026-08-25 | Eric Duane Foster | Chief Commercial Officer | Sell | −8,562 | −$33.02K |
| 2026-07-17 | Michael Raab | President & CEO | MIXED | −20,834 | −$190.30K |
| 2026-06-22 | Laura A Williams | Chief Patient Officer | MIXED | −50,898 | −$459.80K |
| 2026-06-18 | David M Mott | Director | A | +46,737 | — |
| 2026-06-18 | William C Bertrand JR | Director | A | +38,800 | — |
| 2026-06-18 | Muna Bhanji | Director | A | +26,455 | — |
| 2026-06-18 | Onaiza Cadoret-Manier | Director | A | +26,455 | — |
| 2026-06-18 | Richard J Rodgers | Director | A | +26,455 | — |
| 2026-06-18 | Merdad Parsey | Director | A | +26,455 | — |
| 2026-06-18 | Robert B Bazemore | Director | A | +26,455 | — |
| 2026-06-17 | Michael Raab | President & CEO | MIXED | −20,833 | −$215.72K |
| 2026-05-22 | James Parker Brady | Chief Human Resources Officer | Sell | −1,846 | −$11.57K |
| 2026-05-22 | Eric Duane Foster | Chief Commercial Officer | Sell | −7,998 | −$50.13K |
| 2026-05-22 | Joseph James Reilly | See Remarks | Sell | −3,719 | −$23.31K |
| 2026-05-22 | Mike Kelliher | Chief Business Officer | Sell | −7,248 | −$45.43K |
| 2026-05-22 | Susan Hohenleitner | Chief Financial Officer | Sell | −1,455 | −$9.12K |
| 2026-05-22 | Michael Raab | President & CEO | Sell | −54,748 | −$343.13K |
| 2026-05-22 | John E Bishop | See Remarks | Sell | −2,306 | −$14.45K |
| 2026-05-22 | Laura A Williams | Chief Patient Officer | Sell | −6,989 | −$43.80K |
| 2026-05-19 | Michael Raab | President & CEO | MIXED | −20,833 | −$240.99K |
| 2026-04-17 | Michael Raab | President & CEO | MIXED | −20,834 | −$241.33K |
| 2026-03-18 | Michael Raab | President & CEO | MIXED | −20,833 | −$222.70K |
| 2026-02-25 | Michael Raab | President & CEO | MIXED | −20,833 | −$240.00K |
| 2026-02-23 | John E Bishop | See Remarks | Sell | −3,179 | −$18.59K |
| 2026-02-23 | Joseph James Reilly | See Remarks | Sell | −4,991 | −$29.18K |
| 2026-02-23 | Laura A Williams | See Remarks | Sell | −8,176 | −$47.80K |
| 2026-02-23 | Michael Raab | President & CEO | Sell | −45,982 | −$268.84K |
| 2026-02-23 | Mike Kelliher | See Remarks | Sell | −9,595 | −$56.10K |
| 2026-02-23 | James Parker Brady | Chief Human Resources Officer | Sell | −2,543 | −$14.87K |
| 2026-02-23 | Eric Duane Foster | Chief Commercial Officer | Sell | −10,439 | −$61.03K |
| 2026-02-23 | David M Mott | Director | Buy | +333,333 | +$1.95M |
| 2026-02-23 | Susan Hohenleitner | Chief Financial Officer | Sell | −2,033 | −$11.89K |
| 2026-01-27 | Joseph James Reilly | See Remarks | A | +46,200 | — |
| 2026-01-26 | John E Bishop | See Remarks | A | +124,330 | — |
| 2026-01-26 | James Parker Brady | Chief Human Resources Officer | A | +99,455 | — |
| 2026-01-26 | Laura A Williams | Chief Patient Officer | A | +82,695 | — |
| 2026-01-26 | Eric Duane Foster | Chief Commercial Officer | A | +137,945 | — |
| 2026-01-26 | Michael Raab | President & CEO | A | +446,220 | — |
| 2026-01-26 | Mike Kelliher | See Remarks | A | +103,080 | — |
| 2026-01-26 | Susan Hohenleitner | Chief Financial Officer | A | +85,670 | — |
| 2026-01-09 | Laura A Williams | Chief Patient Officer | MIXED | — | −$299.40K |
| 2025-11-25 | Laura A Williams | Chief Patient Officer | Sell | −6,426 | −$35.58K |
| 2025-11-25 | Michael Raab | President & CEO | Sell | −46,887 | −$259.61K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David M Mott | Director | 6,831,841 | $20.09M |
| Michael Raab | President & CEO | 1,644,156 | $4.83M |
| David P. Rosenbaum | Chief Development Officer | 448,378 | $1.32M |
| Richard J Rodgers | Director | 439,998 | $1.29M |
| Eric Duane Foster | Chief Commercial Officer | 415,374 | $1.22M |
| Justin A Renz | Chief Financial Officer | 409,052 | $1.20M |
| Laura A Williams | Chief Patient Officer | 367,456 | $1.08M |
| Mike Kelliher | Chief Business Officer | 351,662 | $1.03M |
| William C Bertrand JR | Director | 329,507 | $968.75K |
| John E Bishop | See Remarks | 317,095 | $932.26K |
| Robert Blanks | See Remarks | 314,421 | $924.40K |
| Elizabeth A Grammer | See Remarks | 302,866 | $890.43K |
| James Parker Brady | Chief Human Resources Officer | 259,090 | $761.72K |
| Susan Hohenleitner | Chief Financial Officer | 227,520 | $668.91K |
| Onaiza Cadoret-Manier | Director | 178,156 | $523.78K |
| Muna Bhanji | Director | 163,808 | $481.60K |
| Joseph James Reilly | See Remarks | 146,964 | $432.07K |
| Merdad Parsey | Director | 83,746 | $246.21K |
| Robert B Bazemore | Director | 68,006 | $199.94K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.